Atezolizumab news

All news on Atezolizumab (also known as Tecentriq): plants, production capacities, investments and involved companies.

12 June 2026

Chugai files Tecentriq for maintenance therapy after definitive chemoradiotherapy in locally advanced esophageal cancer

Submission seeks approval of an anti‑PD‑L1 agent as maintenance therapy after definitive chemoradiotherapy, supported by SKYSCRAPER‑07 Phase III interim results.
10 June 2026

Genentech: FDA grants Priority Review for Tecentriq plus chemotherapy in stage III dMMR/MSI‑H colon cancer

FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
15 May 2026

Genentech’s Tecentriq approved by FDA as ctDNA‑guided adjuvant therapy for MIBC

FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
15 April 2026

Boehringer Ingelheim & Zai Lab launch DLL3‑targeting T‑cell engager + ADC trial in SCLC and NECs

Phase Ib/II testing obrixtamig (DLL3/CD3 T‑cell engager) plus zoci (zocilurtatug pelitecan, DLL3 ADC) in ES‑SCLC and other NECs to assess safety, tolerability and early clinical activity
9 April 2026

Boehringer Ingelheim and BioNTech partner on ES‑SCLC immunotherapy trial

Phase Ib/II trial will test DLL3/CD3 T‑cell engager plus PD‑L1/VEGF‑A bispecific in extensive‑stage SCLC to boost durable antitumor immunity; dosing to start H2 2026
20 October 2025

Roche's Tecentriq Enhances Survival in Bladder Cancer with ctDNA-Guided Treatment

Tecentriq reduces death risk by 41% and recurrence by 36% in bladder cancer using ctDNA guidance, sparing low-risk patients from unnecessary treatment.

Who will be producing Atezolizumab in the future?

Find out with chemXplore Alpha

Learn more

13 October 2025

Roche Highlights Cancer Treatment Advances at ESMO 2025

Roche presents over 30 abstracts on cancer treatments, including breast, lung, and bladder cancers, at ESMO 2025, showcasing significant advancements in progression-free and overall survival.